DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec

First Posted Date: 2011-03-30

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 222

Registration Number: NCT01326026

Locations: 🇪🇸
Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain

Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: placebo
Drug: Microgyn®

First Posted Date: 2011-03-29

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT01324505

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Survey Evaluating the Psychosocial Effects of Living With Haemophilia

Completed

Conditions: Haemophilia B With Inhibitors
Congenital Bleeding Disorder
Haemophilia B
Haemophilia A With Inhibitors
Relatives to/Carers of Patients
Haemophilia A

Interventions: Other: No treatment given

First Posted Date: 2011-03-24

Last Posted Date: 2017-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1236

Registration Number: NCT01322620

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin degludec
Drug: liraglutide

First Posted Date: 2011-03-21

Last Posted Date: 2015-10-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01319240

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Completed

Conditions: Congenital FVII Deficiency
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2011-03-11

Last Posted Date: 2014-10-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01312636

A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2011-02-15

Last Posted Date: 2015-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01296438

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2011-02-02

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 254

Registration Number: NCT01288326

Locations: 🇧🇪
Novo Nordisk Investigational Site, Brussels, Belgium

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: NNC 0128-0000-2011

First Posted Date: 2011-02-02

Last Posted Date: 2016-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01288391

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Completed

Conditions: Acquired Bleeding Disorder
Acquired Haemophilia

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2011-01-27

Last Posted Date: 2014-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01285089

Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC109-0012
Drug: placebo

First Posted Date: 2011-01-24

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 67

Registration Number: NCT01282255

Locations: 🇬🇧
Novo Nordisk Investigational Site, Norwich, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy